Literature DB >> 16500494

Clinical outcomes after cardiac resynchronization therapy: importance of left ventricular diastolic function and origin of heart failure.

Alan D Waggoner1, Aleksandr Rovner, Lisa de las Fuentes, Mitchell N Faddis, Marye J Gleva, Navinder Sawhney, Víctor G Dávila-Román.   

Abstract

BACKGROUND: Cardiac resynchronization therapy (CRT) improves functional outcomes in patients with severe systolic heart failure. Whether the effects of CRT on left ventricular (LV) diastolic function and clinical outcomes are influenced by the cause as either ischemic or nonischemic cardiomyopathy (CM) has not been well established.
METHODS: A total of 57 patients (age 60 +/- 11 years; 25% women; LV ejection fraction 25 +/- 5%) were studied before and 4 +/- 2 months after CRT by echocardiography. Heart failure cause was ischemic CM in 19 and nonischemic CM in 38. Measurements of LV systolic and diastolic function were determined by 2-dimensional and Doppler echocardiography with Doppler tissue imaging of regional myocardial velocities. Clinical outcome events were assessed at long-term follow-up and included hospitalization for heart failure exacerbation, heart transplantation, or cardiac-related death.
RESULTS: There were significant increases in LV ejection fraction, reductions in end-systolic volumes, and improved LV systolic dyssynchrony in both groups. However, significant improvements in LV diastolic function were observed only in the patients with nonischemic CM. Clinical events occurred in 53% of the ischemic group versus 26% of the nonischemic group (P < .05) after 20 +/- 11 months of CRT. Univariate and multivariate analysis revealed that Doppler-estimated LV filling pressures were predictors of clinical outcome events.
CONCLUSIONS: After CRT patients with ischemic CM exhibit lack of improvement in LV diastolic function despite favorable effects on LV systolic performance. The Doppler-derived LV filling indices may be an important predictor of long-term clinical outcomes after CRT.

Entities:  

Mesh:

Year:  2006        PMID: 16500494     DOI: 10.1016/j.echo.2005.10.014

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  6 in total

Review 1.  The relationship between cardiac resynchronization therapy and diastolic function.

Authors:  Gregory F Egnaczyk; Eugene S Chung
Journal:  Curr Heart Fail Rep       Date:  2014-03

2.  Left ventricular diastolic dyssynchrony assessed with phase analysis of gated myocardial perfusion SPECT: a comparison with tissue Doppler imaging.

Authors:  Mark J Boogers; Ji Chen; Caroline E Veltman; Rutger J van Bommel; Eline A Q Mooyaart; Imad Al Younis; Bernies van der Hiel; Petra Dibbets-Schneider; Ernst E van der Wall; Martin J Schalij; Ernest V Garcia; Jeroen J Bax; Victoria Delgado
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-18       Impact factor: 9.236

3.  Abnormal diastolic function underlies the different beneficial effects of cardiac resynchronization therapy on ischemic and non-ischemic cardiomyopathy.

Authors:  Qi Wang; Kang-Yu Chen; Fei Yu; Hao Su; Chun-Sheng An; Yang Hu; Dong-Mei Yang; Jian Xu; Ji Yan
Journal:  Clinics (Sao Paulo)       Date:  2017-07       Impact factor: 2.365

4.  Impact of etiology on the outcomes in heart failure patients treated with cardiac resynchronization therapy: a meta-analysis.

Authors:  Yanmei Chen; Chongyang Duan; Feng Liu; Shuxin Shen; Pingyan Chen; Jianping Bin
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

5.  Etiologic impact on difference on clinical outcomes of patients with heart failure after cardiac resynchronization therapy: A systematic review and meta-analysis.

Authors:  Jian-Shu Chen; Xiao-Wei Niu; Fen-Mei Chen; Ya-Li Yao
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

6.  Diastolic dyssynchrony and its exercise-induced changes affect exercise capacity in patients with heart failure with reduced ejection fraction.

Authors:  Jakub Stępniewski; Grzegorz Kopeć; Wojciech Magoń; Piotr Podolec
Journal:  Cardiol J       Date:  2019-04-17       Impact factor: 2.737

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.